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Community-acquired pneumoniaThe role of procalcitonin (PCT) as a biomarker for sepsis in adults is well documented, while its role in infections
affecting neonatal children remains controversial. Among these infections, Community-Acquired pneumonia
(CAP) has been studied extensively, because it's the second cause of death in children in developing countries,
and one of the most frequent causes of hospitalization in industrialized countries.
The PubMed database and the Cochrane Library were used to search for the following keywords: CAP,
procalcitonin, and children. Thirteen articles were studied to determine the role of PCT in CAPmanagement, spe-
ciﬁcally its usefulness for distinguishing pneumococcal infections from viral and unknown infections, for
predicting severity and the correct antibiotic treatment. This paper focuses on the studies performed to identify
the best inﬂammatory biomarker for CAP management.
Although there is an increase in studies conﬁrming the usefulness of PCT in CAPmanagement in children, further
studies are needed to have better understanding of its role for pediatric CAP management.
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The physiological role of procalcitonin (PCT) remains unknown. PCT,
a protein containing 116 amino acids, is normally produced by neuroen-
docrine cells in the thyroid and lungs at a very low rate and it is unde-
tectable in serum [1]. Inﬂammatory and infectious injuries stimulate
overexpression of the CALC1 gene consequently increasing serum PCT.-acquired pneumonia; CRP, C-
BC, white blood cells; ROC, re-
ve; CI, conﬁdence interval; OR,
ogia e Biotecnologie Mediche,
27 Palermo, Italy.
).Under these pathologic conditions, synthesis and secretion of PCT be-
come ubiquitous [2].
The role of procalcitonin (PCT) as a biomarker for sepsis in adults is
well documented, while its role in infections affecting neonatal children
remains controversial [3]. Among these infections, Community-Acquired
pneumonia (CAP) has been studied extensively, because it's the second
cause of death in children in developing countries, and one of the most
frequent causes of hospitalization in industrialized countries [4]. Al-
though the signiﬁcance of serum PCT levels at diagnosis is observed in
adult systemic inﬂammation, its relevance in pediatric CAP is still uncer-
tain [5]. The main objective of several clinicians and investigators in this
ﬁeld has been to detect the cause of pneumonia: since bacterial Pneumo-
nia cannot be completely differentiated on the basis of clinical or chest
radiograph ﬁndings, many efforts have been made with the goal to im-
prove early detection of etiologic agents via biomarkers, particularly
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cessively, itwas important to focus on the role of PCT for assessing the se-
verity of the disease and for managing the antibiotic treatment.
This study focuses on the role of PCT in pediatric CAP management.
2. Method
The PubMed database and the Cochrane Library were used to search
for the following keywords: CAP, procalcitonin, and children. Forty-four
hits were obtained from PubMed: 30 papers and 1 review that investi-
gate the role of PCT in adults instead of children were excluded; the
same search was performed in the Cochrane Library and 2 articles, al-
ready taken from PubMed,were found. The 13 remaining articles includ-
ed 4 observational studies, 3 prospective studies, 1 retrospective single
center cohort study, 1 prospective single center randomized study, 1 pro-
spective control case study, 1 prospective cohort study, 1 prospective
and descriptive study and 1 review. An additional 7 articles, 1 review
and 2 clinical practice Guidelines were speciﬁcally searched for as refer-
ences for this study's “background”, “PCT and disease severity” and “PCT
and antibiotic treatment” sections.We limited the search to studies pub-
lished in English, and that were conducted using clinical case studies.
3. PCT and CAP etiology
Several authors [6–14] have investigated the role of PCT as a serum
marker for differentiating bacterial and viral CAP in children, individually
or combinedwith other inﬂammatorymarkers. Generally, two hypothe-
ses emerged: one conﬁrming the usefulness of PCT in distinguishing the
etiology of CAP, the other ﬁnding no usefulness.
In 2000, the study by Toikka et al. [6] showed that patients with bac-
terial pneumonia had a signiﬁcantly higher PCT (median 2.09 ng/ml vs
0.56 ng/ml, p = 0.019) and a CRP (C-reactive protein) concentration
(96 mg/l vs 54 mg/l p = 0.08), in 126 children (inpatients from the
ages of 1 month to 17 years). Using PCT N 2 ng/ml, the sensitivity was
50% and the speciﬁcity was N80% for bacterial pneumonia. The authors
concluded that PCT and CRP values greatly overlapped.
In 2001, Moulin et al. [7] investigated the role of several markers for
the rapid identiﬁcation of bacterial vs viral pneumonia in 72 children
(inpatients form the ages 2 months to 13 years), ﬁnding that the PCT
value of 1 ng/ml differentiates between bacterial infection and viral
pneumonia more effectively (AUC: 0.93; 95% CI 0.85–0.97) than CRP
(AUC: 0.84, 95% CI 0.73–0.91), and interleukin 6 (IL-6) (AUC 0.64, 95%
CI 0.45–0.80).
The study by Korppi [8] assessed the value of the clinical features in
CAP for differentiating the etiology between viral, pneumococcal and
atypical infections. By comparing these characteristics in 101 children
(mean age: 4 years; 27% inpatients), the three nonspeciﬁc markers of
typical bacterial CAP (alveolar inﬁltration, elevated PCT and need of hos-
pital care), with PCT values ≥1 ng/ml and age ≥ 5,were determined to be
independently predictive factors for bacterial CAP (distinction of bacte-
rial from viral etiology of CAP: OR 4.1; CI 95% 1.0–16.6).
In 2010, the study by Lee et al. [9] compared PCT levels and other in-
ﬂammatory markers between bronchopneumonia and lobar pneumo-
nia in 76 children (mean age: 3 years; inpatients) and investigated the
test performance by plotting a Receiver Operating Characteristic curve
(ROC), expressed in terms of sensitivity, speciﬁcity and likelihood
ratio (LR); the areas under the curves were calculated. PCT AUC at the
time of admissionwas 0.83, 95% CI 0.65–0.99; themaximum LR for pos-
itive results (15.3) (LR+)was reached at a cut-off of 2 ng/ml. Results for
the other inﬂammatory markers are reported below in the section “PCT
vs other inﬂammatory markers”.
In 2010, theNascimento study [10] showed that in 95 children (aged
26 days to 4.8 years; inpatients) PCT had a negative predictive value for
differentiating bacteraemic infections from viral infections, atypical bac-
terial infections and non-bacteraemic typical bacterial infections,(respectively 95%, 89%, 93%) at a threshold N2 ng/ml. In addition, PCT
was useful to differentiate between bacterial and viral infection (58%).
Recently, the Galetto-Lacour study [11] conﬁrmed the role of PCT in
differentiating the etiology of CAP, particularly showing elevated PCT
and CRP values to be strongly associated with pneumococcal CAP (OR:
23, 95% CI: 5–117; OR: 19, 95% CI: 5–75, respectively). Speciﬁcally, the
authors suggested that elevated PCT or CRP values are stronger predic-
tors of pneumococcal CAPwhen associatedwith a positive pneumococ-
cal urinary antigen.
In order to discuss the studies with contradicting results [12–14] to
the ones previously described, it could be useful to point out the results
obtained by Korppi, which initially focused on the hypotheses that ex-
cluded the role of PCT in distinguishing the infection etiology. However,
at a later stage the role of PCT was proven to be useful, as seen above
[11–13]. Particularly, in 2001, no difference between pneumococcal,
viral, mixed and unknown CAP patient subgroups was reported in 119
children from a sample of 132 children (mean age: 3 years; inpatients).
PCT values of 0.5, 1.0 and 2.0 ng/ml were tested as screening limits be-
tween pneumococcal, viral and unknown pneumonia. The highest sen-
sitivity was 55% at the 0.5 ng/ml cut-off level. The highest speciﬁcity
(88%) was reached at 1.0 ng/ml. The Likelihood Ratio (LR) for positive
results was 2.6, and for negative results 0.6, which is irrelevant. The
ROC curve showed no cut-off limitwith a good sensitivity and speciﬁcity
for distinguishing between pneumococcal and viral pneumonia (AUC of
serum PCT for differentiating viral from bacterial infections: 0.5).
In the study that included 190 children (aged 0–15, 30.5% inpa-
tients) with CAP, Korppi [13] found no differences between pneumo-
coccal, mycoplasma/chlamydia, viral and unknown etiology infections,
in terms of PCT values. The results were similar when the single strain
pneumococcal infections (0.39 ng/ml) and themixed pneumococcal in-
fections (0.49 ng/ml) were analyzed separately.
The research by Don et al. [14] found no association between PCT
levels and etiology in 68 children (b 5 years: 63%, N5 years: 37%; 19% in-
patients), at all cut-offs, which were the 25th, 50th, 75th and 90th per-
centile levels, corresponding respectively to 0.4, 1.0, 18 and 35.8 ng/ml.
4. PCT and disease severity
While the relationship between PCT and severity or prognosis has
been thoroughly investigated in adults during either systemic infections
or CAP [15–16], only few authors [17–19] have looked into the relation-
ship between PCT values and severity for pediatric infectious diseases.
Speciﬁcally, in the cases of bacterial infections, such as meningococcal
disease and urinary tract infections, or bacterial sepsis, there is an asso-
ciation between high PCT levels and poor prognosis. With regard to
assessing CAP severity via PCT concentrations, in 2007 Don [20] con-
ducted a prospective study performed on 100 children (mean age: 3.7
years; 26% inpatients) with the goal to evaluate the level of PCT while
assessing severity of CAP, expressed in terms of needing hospital treat-
ment and the presence of an alveolar inﬁltration on chest radiograph.
PCT concentration showed signiﬁcant difference in inpatients compared
to outpatients (p b 0.0012). Likewise, PCT levels in alveolar CAP (25th–
75th percentiles: 0.54–22.87) were signiﬁcantly higher (p b 0.0003)
than levels in interstitial CAP (25th–75th percentiles: 0.31–1.04).
5. PCT and antibiotic treatment
Antibiotic treatment of CAP in children remainsmostly empirical be-
cause the identiﬁcation of etiologic pathogen is difﬁcult in pediatric pa-
tients. The European andAmerican guidelines [21–22] recommendbeta
lactam treatment as the ﬁrst choice in hospitalized children of all ages,
to target Streptococcus pneumoniae. In 95% of children with bacterial
pneumococcal CAP, apyrexia is reached within 48 h of antibiotic treat-
ment. Since no biological predictor of clinical response to beta lactam
treatment is available, in 2012 Cohen et al. [23] performed a retrospec-
tive study on 125 CAP children (mean age: 3.1 years; inpatients) treated
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dictor of clinical response in terms of diagnostic performance (sensitiv-
ity, speciﬁcity, likelihood ratio and predictive value) among PCT, WBC
count, neutrophil count and CRP. PCT levels were signiﬁcantly higher
in children with, rather than without, a response to beta lactam treat-
ment (3.7 ng/ml, 1–9.4, vs 0.7 ng/ml, 0.2–2.9; p = 0.05). A multivariate
analysis identiﬁed PCT and neutrophil count asmore reliable predictors
thanWBC count and CRP (p b 0.002, 0.04 vs 0.06 and 0.13, respectively).
An Italian [24] study performed on 319 children (aged 1month to 14
years; inpatients), used PCTmeasurements to guide antibiotic treatment
choices. The study design implied that all patients were divided into two
subgroups: a PCT-guided therapy group, and an evidence-based therapy
group. The former underwent antibiotic therapy based on PCT values
(≥0.25 ng/ml). The study found that the PCT group received signiﬁcantly
fewer courses of antibiotics (85.8% vs 100%; p b 0.05),was exposed to an-
tibiotics for less time (5.37 vs 10.96 days; p b 0.05), and experienced
fewer adverse effects to antibiotic treatment (3.9% vs 25.2%; p b 0.05).
6. PCT vs other inﬂammatory markers
A great effort has been made in order to assess the role of PCT and
other inﬂammatory nonspeciﬁc markers, individually and in combina-
tion, in CAP management, as well as for detecting etiologic features, in
assessing disease prognosis and severity, or in predicting clinical re-
sponse to antibiotic treatment. Speciﬁcally, two research groups [6,14]
have tested the diagnostic performance of the above-mentioned predic-
tors with the goal to identify the best one, by assessing the diagnostic
characteristics at different thresholds for each one. Since each study
has been carried out using different methodological approaches, from
the enrollment criteria to laboratory analysis, different cut-offs have
been used to assess the diagnostic performance of each marker and to
eventually identify the best predictor [6,10,12,14]. Toikka [6], in 2000,
and Moulin [7], in 2001, chose to evaluate IL-6 in addition to PCT and
CRP, in order to assess the etiology of CAP. The results were similar
when analyzing the comparison between PCT and IL-6 diagnostic per-
formances, showing PCT to be more accurate than IL6, while they con-
ﬂicted when comparing PCT and CRP. In particular, the results of
Toikka showed that using PCT N 2 ng/ml, CRP N 150 ng/ml or IL6 N 40
pg/ml, the speciﬁcity was N80% for bacterial pneumonia for all the
markers; while the sensitivities with these cut-off values were 50% for
PCT, 31% for CRP and 34% for IL-6. As seen before, Toikka found that
CRP and PCT values greatly overlapped. However, the results reported
by Moulin showed that the concentration PCT, with a threshold of 2
ng/ml, is more sensitive and speciﬁc and has greater positive and nega-
tive predictive values than CRP, IL6 or white blood cell count for differ-
entiating bacterial and viral causes of community-acquired pneumonia.
The areas under the ROC curves were compared for all of the markers,
except WBC count: p b 0.04 PCT vs CRP, and p b 0.003 for PCT vs IL-6.
The study by Nascimento-Carvalho [10] evaluated the cytokine IFN-
α in addition to PCT, in relation to its usefulness in differentiating viral
from bacterial etiology among children with bacteraemic CAP. The re-
sults showed an association between the presence of detectable IFN-α
and PCT b 2 ng/ml (p b 0.02). The authors concluded that the presence
of IFN-α did not add any diagnostic value to PCT in distinguishing be-
tween the different etiological groups.
In 2009, Don et al. [14] evaluated the role of the main inﬂammatory
markers, excluding cytokines, by analyzing the association between
ﬁve different combinations of PCT, CRP, WBC count and ESR and the eti-
ology of pneumonia. The results showed that for all four of the marker
values N50th percentile (CRP: 101 mg/l; WBC: 15.34 cells × 109/l; PCT:
1 ng/ml; ESR: 65 mm/h), the likelihood ratio for positive results (LR+)
was 2.7 for separating pneumococcal from viral CAP, and 3.91 for
distinguishing atypical from viral CAP. When considering PCT alone at
75th percentile (18 ng/ml), it had a LR+ of 4.14 for distinguishing a
pneumococcal from viral etiology, while it was 3.4 in atypical vs viral
CAP. The authors concluded that elevated CRP, PCT and WBC had nosigniﬁcant association with the etiology of CAP. However, values of ESR
at 50th and 75th percentiles (60mm/h, 90mm/h) andWBC at 75th per-
centile (22 cells × 10/l) were signiﬁcantly associatedwith the etiology of
the infection.
In 2004, Korppi [25] investigated the role of the combination of four
inﬂammatory markers (PCT, CRP, WBC, ESR), and chest radiographic
ﬁndings for differentiating pneumococcal from viral etiology in 132
children (inpatients from the ages of 1 month to 5 years). Using the
25th, 50th, 75th and 90th percentile values of eachmarker, the sensitiv-
ity, speciﬁcity and likelihood ratio for positive results were calculated
and, based on the likelihood ratio value, the most accurate combination
was selected. The authors concluded that there was no sensitive and
speciﬁc combination of these markers that could be used in the clinical
pediatric practice. Lee et al. [9] obtained similar results when comparing
the samemarkers in childrenwith lobar pneumonia. They found that LR
of PCT for diagnosis of lobar pneumoniawasmaximumat a cut-off value
of 2 ng/ml, LR being higher than the CRP level at a cut-off of 6mg/L (6.9)
and the ESR at a cut-off of 30 mm/h (6.8).
With regard to the role of PCT, CRP, ESR andWBC count in assessing
disease severity, the study by Don [20] showed that the severity of
pneumonia, evaluated by the need for hospital treatment and the pres-
ence of an alveolar inﬁltration on chest radiograph, was associatedwith
a signiﬁcant elevation of the average serum PCT concentrations com-
pared to outpatients, and that there was a good correlation between
PCT and CRP (r = 0.72), WBC (r = 0.59), and only a moderate correla-
tion with ESR (r = 0.43).
Cohen [23] performed an analysis of predictors (PCT, CRP, WBC
count and ESR), with regard to the role of inﬂammatory markers in
predicting clinical response to antibiotic treatment, and assessed the
usefulness of PCT compared with the three other markers.7. Conclusion
The management of CAP in children still requires useful laboratory
tools either for detecting the etiology agent, with the goal to start the
correct antibiotic treatment sooner and to reduce antibiotic courses, or
for predicting prognosis of the disease. Among the biomarkers, PCT
and CRP have been carefully studied and compared, leading to contro-
versial results. In addition, other markers for inﬂammation have been
proposed for CAP diagnosis andmanagement, such as the soluble uroki-
nase plasminogen activator receptor (suPAR), however in this case
there is still no deﬁnitive data [26,27,28]. Overall, the most recent data
showed PCT to be the best performance diagnostic marker, especially
in terms of detection of a pneumococcal infection [29,30]. Asmentioned
previously, PCT could lead to early beta lactam therapy, given that it's a
predictor of pneumococcal pneumonia.
Unfortunately, the studies reported in this review have some limita-
tions: ﬁrstly, sample sizes are small; furthermore, most of them involve
children with uncomplicated CAP. Thus, it's still unknown whether
there is an advantage in severe and complicated CAP. Currently, the
use of CRP in clinical practice has not been replaced by PCT, probably
due to its higher cost compared CRP, and to its limited availability. Nev-
ertheless, there is an increase in results conﬁrming the usefulness of PCT
for the management pediatric CAP, but further studies are needed for a
better understanding its role.References
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